Tirzepatide is medicine delivered by a shot beneath the skin. What does the tirzepatide dosage label say, and why did study amounts rise?

Why did treatment begin with a smaller amount?

Tirzepatide remains in blood between the weekly study shots. This page explains amounts on the prescribing label and their study results. The label begins at 2.5 milligrams for type 2 diabetes and obesity. Milligrams measure medicine inside the shot, rather than a person's weight.

The smaller start helps limit stomach trouble while the body adjusts. Label amounts rise at four-week intervals toward an ongoing treatment amount. Trials tested 5 milligrams, 10 milligrams, or 15 milligrams each week. SURMOUNT-1's greatest average loss was 20.9% with 15 milligrams over 72 weeks.

After five days, blood still holds about half the medicine. That lasting presence helps explain why study shots were given weekly. These amounts come from both prescribing labels and published treatment studies. Your prescriber decides the amount for your health and other medicines.

Which increases does the Tirzepatide dosage label describe?

The prescribing label describes gradual increases intended to limit stomach trouble ^[6]. Each amount below is measured in milligrams of medicine. Your prescriber decides how those label details apply to your care.

• Weeks 1–4: The listed starting amount is 2.5 milligrams weekly. This gives time to adjust. It isn't the amount for ongoing treatment.
• Weeks 5–8: The label next lists 5 milligrams each week. The smaller starting amount comes first. Later increases depend on unwanted effects.
• Weeks 9–12: The next possible amount is 7.5 milligrams weekly. Otherwise, treatment remains at 5 milligrams. The decision depends on tolerating treatment.
• Weeks 13–16: The label next lists 10 milligrams per week. An increase depends on tolerating treatment. Stomach trouble can delay the change.
• Weeks 17–20: The next listed amount is 12.5 milligrams weekly. Further increases depend on unwanted effects. These are label details for medical care.
• Weeks 21+: The largest listed amount is 15 milligrams weekly. This amount must also be tolerated. The largest amount doesn't suit every patient.

Phase 3 studies were the large tests of treatment benefits and harms. These studies compared 5 milligrams, 10 milligrams, and 15 milligrams ^[4]. SURMOUNT-1 allowed a 20-week period to reach each assigned amount. A lower assigned amount didn't mean progressing toward the highest amount.

What weight changes followed each Tirzepatide dose?

SURMOUNT-1 compared tirzepatide shots with placebo shots containing none of that medicine ^[4]. Milligrams measure the amount of medicine given each week. The losses below describe average changes from weight before treatment.

• 5 milligrams weekly: Loss averaged 15.0% over 72 weeks. The placebo loss was 3.1%. Patients differed around those averages.
• 10 milligrams weekly: Loss averaged 19.5% over 72 weeks. The placebo result was 3.1%. Your result could be different.
• 15 milligrams weekly: Loss averaged 20.9% over 72 weeks. The placebo average was 3.1%. More medicine brought greater average loss.

SURPASS-2 studied adults with type 2 diabetes using a sugar test ^[3]. The blood test shows average sugar across roughly three months. Every tirzepatide group had greater average sugar improvement than the comparison group.

• 5 milligrams weekly: Sugar improved by week 40. Patients had different changes. These are study findings.
• 10 milligrams weekly: Sugar improved by week 40. Average improvement was greater. Patients still had different results.
• 15 milligrams weekly: Sugar improved by week 40. Average improvement was greatest. Results don't decide personal care.

Semaglutide 1 milligram improved sugar less than each tirzepatide amount. Each tirzepatide group also lost more weight in SURPASS-2 ^[3]. Both sugar and weight therefore improved more with tirzepatide.

2026: SURMOUNT-MAINTAIN examined continuing at 5 milligrams ^[12]. At week 112, total loss was 16.6%, against 9.9% with placebo. Continuing medicine preserved much of the loss.

Where does the Tirzepatide injection go after the shot?

A tirzepatide injection delivers medicine beneath belly, thigh, or upper-arm skin. Medicine then enters the blood from the area of the shot. Neither swallowed pills nor medicine delivered into a vein have approval ^[6]. Your prescriber explains the approved product supplied in your care.

A fatty attachment grips a protein circulating in the blood ^[7]. The attachment delays removal because medicine stays with the blood protein. Blood still holds roughly half five days later, helping explain weekly treatment. Blood levels change between shots despite the medicine's slower removal.

Weekly treatment produces steadier blood levels after four to five weeks. Similar rises and falls then repeat between the weekly shots. The medicine stays longer than the hormones released after meals. Your prescriber considers that lasting effect when planning medical care.

Researchers measured medicine levels when people's livers worked less well ^[31]. The measured levels didn't call for a change in medicine amount. Other studies examined levels during diabetes and weight treatment ^[7]. Your doctor still considers other illnesses alongside those findings.

Trial medicine was liquid delivered through a shot beneath the skin. The products described require storage in a refrigerator between treatments. Preparation and storage depend on the particular product supplied. The product's directions, rather than weight-loss results, explain those details.

Which amounts were studied in Tirzepatide vs semaglutide?

SURMOUNT-5 compared weight treatments in obesity; patients had no type 2 diabetes ^[5]. Tirzepatide amounts were 10 or 15 milligrams; semaglutide amounts were 1.7 or 2.4 milligrams weekly. Milligrams measure medicine inside each shot, rather than lost weight. Patients reached the greatest study amount their bodies could tolerate.

At week 72, the tirzepatide group's average loss was 20.2%. The semaglutide group's average weight loss was 13.7%. The amounts were chosen for tolerance, rather than matched milligram for milligram. Your doctor considers that difference when explaining which study answers which question.

SURPASS-2 studied type 2 diabetes over 40 weeks ^[3]. Tirzepatide 15 milligrams brought more weight loss than semaglutide 1 milligram. That semaglutide amount was lower than the 2.4 milligrams in weight studies. This diabetes comparison therefore differs from the comparison for obesity.

Sugar improved more with tirzepatide 15 milligrams in the diabetes study. Semaglutide 1 milligram brought less improvement in the average sugar test. All tested tirzepatide amounts improved sugar more, beyond a readily explained chance difference.